EuropaBio Calls for More Transparency of Biosimilar Labels
EuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency in the label.
EuropaBio members believe that the current EU approach to labeling does not reflect the specificities of biosimilars and that the SmPC of a biosimilar product should contain additional information to facilitate greater transparency for physicians and patients.
Based on interactions that EuropaBio had with various stakeholders including physicians and patients over recent years, we have concluded that label transparency would be enhanced by implementing the following small yet meaningful changes to the biosimilar SmPC:
- Adding a statement with the definition of biosimilarity
- Adding a direct link to the EPAR next to the biosimilarity statement
- Moving the biosimilarity statement to the top of the SmPC
“The EMA and the European Commission are going to great lengths to increase physicians’ and patients’ understanding of biosimilars”, said Ronald Jager, EuropaBio Healthcare Biotech Director, “We are convinced that a more transparent labeling approach would contribute to further facilitate the understanding and acceptance of biosimilars.”
FDA Approves Opdivo Plus Yervoy Regimen for MSI-H/dMMR Colorectal Cancer
April 9th 2025Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was the largest immunotherapy study in patients with previously untreated, unresectable, or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
